• Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=26405815).
  
• Mutation; HGNC; HGNC:9588; PTEN; Simple; p.Arg173His (c.518G>A); ClinVar=VCV000376032; Zygosity=Unspecified (ATCC=CRL-3226).
  

PubMed=7681084; DOI=10.4049/jimmunol.150.7.2955
Craig L. Slingluff Jr., Andrea L. Cox, Ralph A. Henderson, Donald Frederick Hunt, Victor H. Engelhard;
Recognition of human melanoma cells by HLA-A2.1-restricted cytotoxic T lymphocytes is mediated by at least six shared peptide epitopes.
J. Immunol. 150:2955-2963(1993)

PubMed=10752474; DOI=10.1007/s002620050015; PMCID=PMC11037162
Craig L. Slingluff Jr., Teresa A. Colella, Lee Thompson, D. David Graham, Jonathan C.A. Skipper, Jennifer Caldwell, Larry Brinckerhoff, David J. Kittlesen, Donna H. Deacon, Correen Oei, Nancy L. Harthun ...Show all 15 authors... , Eric L. Huczko, Donald Frederick Hunt, Timothy L. Darrow, Victor H. Engelhard; Show fewer authors
Melanomas with concordant loss of multiple melanocytic differentiation proteins: immune escape that may be overcome by targeting unique or undefined antigens.
Cancer Immunol. Immunother. 48:661-672(2000)

PubMed=14871852; DOI=10.1158/0008-5472.CAN-03-2209
Kevin T. Hogan, Michael A. Coppola, Christine L. Gatlin, Lee W. Thompson, Jeffrey Shabanowitz, Donald Frederick Hunt, Victor H. Engelhard, Mark M. Ross, Craig L. Slingluff Jr.;
Identification of novel and widely expressed cancer/testis gene isoforms that elicit spontaneous cytotoxic T-lymphocyte reactivity to melanoma.
Cancer Res. 64:1157-1163(2004)

PubMed=15905528; DOI=10.4049/jimmunol.174.11.6863
Galina V. Yamshchikov, David Warren Mullins, Chien-Chung Chang, Takeshi Ogino, Lee Thompson, Jennifer Presley, Holly Galavotti, William Aquila, Donna H. Deacon, William Ross, James W. Patterson ...Show all 14 authors... , Victor H. Engelhard, Soldano Ferrone, Craig L. Slingluff Jr.; Show fewer authors
Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma.
J. Immunol. 174:6863-6871(2005)

PubMed=20856146; DOI=10.1097/CMR.0b013e32833fafb4; PMCID=PMC3229868
Leann M. Mikesh, Manish Kumar, Gulsun Erdag, Kevin T. Hogan, Kerrington R. Molhoek, Marty W. Mayo, Craig L. Slingluff Jr.;
Evaluation of molecular markers of mesenchymal phenotype in melanoma.
Melanoma Res. 20:485-495(2010)

PubMed=21654344; DOI=10.1097/CMR.0b013e328343a1d6; PMCID=PMC3131461
Kerrington R. Molhoek, Amber L. Shada, Mark Smolkin, Sudhir Chowbina, Jason Papin, David L. Brautigan, Craig L. Slingluff Jr.;
Comprehensive analysis of receptor tyrosine kinase activation in human melanomas reveals autocrine signaling through IGF-1R.
Melanoma Res. 21:274-284(2011)

PubMed=26405815; DOI=10.1371/journal.pone.0138210; PMCID=PMC4583389
Brian J. Capaldo, Devin Grimm Roller, Mark J. Axelrod, Alexander F. Koeppel, Emanuel F. Petricoin 3rd, Craig L. Slingluff Jr., Michael J. Weber, Aaron J. Mackey, Daniel Gioeli, Stefan Bekiranov;
Systems analysis of adaptive responses to MAP kinase pathway blockade in BRAF mutant melanoma.
PLoS ONE 10:e0138210.1-e0138210.25(2015)

PubMed=26673621; DOI=10.18632/oncotarget.6548; PMCID=PMC4823068
Devin Grimm Roller, Brian J. Capaldo, Stefan Bekiranov, Aaron J. Mackey, Mark Robert Conaway, Emanuel F. Petricoin 3rd, Daniel Gioeli, Michael J. Weber;
Combinatorial drug screening and molecular profiling reveal diverse mechanisms of intrinsic and adaptive resistance to BRAF inhibition in V600E BRAF mutant melanomas.
Oncotarget 7:2734-2753(2016)